Literature DB >> 21479360

A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.

Hiroki Iwata1, Hiromi Sato, Rina Suzuki, Ryota Yamada, Saki Ichinomiya, Midori Yanagihara, Hiroyuki Okabe, Yuko Sekine, Tomohiro Yano, Koichi Ueno.   

Abstract

Renal cell carcinoma (RCC) is resistant to chemo-therapy partly due to the overexpression of the P-glycoprotein. Several tumor suppressor genes have been reported to be silenced by hypermethylation of the promoter region in RCC. We recently reported that the in vitro cytotoxicity of vinblastine (VBL) was enhanced by pre-treatment with the demethylating agent, 5-aza-2'-deoxycytidine (Aza), in the RCC cell line, Caki-1. In this study, we investigated the combined effect of Aza and VBL in a Caki-1 xenograft model and in other RCC cell lines in vitro. In the xenograft model, tumor volume and weight were significantly suppressed in the co-treatment group, compared to the control, and the expressions of P-glycoprotein, Bcl-2 and cyclin B1 were reduced. Thus, this combined effect could be mediated by the accumulation of intracellular VBL and the enhancement of apoptosis and cell cycle arrest. More-over, the cytotoxicity of VBL was enhanced in vitro in three RCC cell lines by Aza treatment. These findings suggest that the combination treatment with Aza and VBL is effective against RCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479360     DOI: 10.3892/ijo.2011.999

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.

Authors:  Min-Li Mo; Jie Ma; Zhao Chen; Bing Wei; Hui Li; Yong Zhou; Huaiyin Shi; Bhairavi Tolani; Joy Q Jin; Hsin-Hui Tseng; Dong Shen; Yi Zhan; Jun Li; David M Jablons; Rong-Qing Zhang; Yongjun Guo; Biao He; Hai-Meng Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-04       Impact factor: 4.553

2.  In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin.

Authors:  Dong Wang; Xiaohou Wu
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

Review 3.  Manipulating the epigenome for the treatment of urological malignancies.

Authors:  Colm J O'Rourke; Vinicius Knabben; Eva Bolton; Diarmaid Moran; Thomas Lynch; Donal Hollywood; Antoinette S Perry
Journal:  Pharmacol Ther       Date:  2013-01-24       Impact factor: 12.310

Review 4.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

5.  Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors.

Authors:  Jean-Pierre Issa; Ignacio I Wistuba; Razelle Kurzrock; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta
Journal:  Clin Epigenetics       Date:  2014-01-09       Impact factor: 6.551

6.  Polyphenol extract from Phellinus igniarius protects against acrolein toxicity in vitro and provides protection in a mouse stroke model.

Authors:  Papawee Suabjakyong; Ryotaro Saiki; Leo J L D Van Griensven; Kyohei Higashi; Kazuhiro Nishimura; Kazuei Igarashi; Toshihiko Toida
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 7.  One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling.

Authors:  Joshua M Corbin; Maria J Ruiz-Echevarría
Journal:  Int J Mol Sci       Date:  2016-07-27       Impact factor: 5.923

Review 8.  Targeting DNA Methyltranferases in Urological Tumors.

Authors:  Ângela Marques-Magalhães; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

9.  Primary TSC2-/meth Cells Induce Follicular Neogenesis in an Innovative TSC Mouse Model.

Authors:  Clara Bernardelli; Eloisa Chiaramonte; Silvia Ancona; Silvia M Sirchia; Amilcare Cerri; Elena Lesma
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

10.  Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.

Authors:  Lixin Wang; Jianmin Luo; Guofeng Chen; Meiyun Fang; Xudong Wei; Yinghua Li; Zhuogang Liu; Yin Zhang; Sujun Gao; Jianliang Shen; Xin Wang; Xiaoning Gao; Wei Zhou; Yigai Ma; Hui Liu; Xinquan Li; Linhua Yang; Kai Sun; Li Yu
Journal:  Clin Epigenetics       Date:  2020-09-01       Impact factor: 6.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.